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Introduction: During recent years, there has been growing interest in use of topical vehicle 
systems to assist in drug permeation through the skin. Drugs of interest are usually those that 
are problematic when given orally, such as piroxicam, a highly effective anti-inflammatory, anti-
pyretic, and analgesic, but with the adverse effect of causing gastrointestinal ulcers. The   present 
study investigated the in vitro and in vivo pharmacodynamic activity of a newly   synthesized 
palm oil esters (POEs)-based nanocream containing piroxicam for topical delivery.
Methods: A ratio of 25:37:38 of POEs: external phase: surfactants (Tween 80:Span 20, in a ratio 
80:20), respectively was selected as the basic composition for the production of a nanocream 
with ideal properties. Various nanocreams were prepared using phosphate-buffered saline as the 
external phase at three different pH values. The abilities of these formulae to deliver piroxicam 
were assessed in vitro using a Franz diffusion cell fitted with a cellulose acetate membrane and 
full thickness rat skin. These formulae were also evaluated in vivo by comparing their anti-
inflammatory and analgesic activities with those of the currently marketed gel.
Results: After eight hours, nearly 100% of drug was transferred through the artificial membrane 
from the prepared formula F3 (phosphate-buffered saline at pH 7.4 as the external phase) and 
the marketed gel. The steady-state flux through rat skin of all formulae tested was higher than 
that of the marketed gel. Pharmacodynamically, nanocream formula F3 exhibited the highest 
  anti-inflammatory and analgesic effects as compared with the other formulae.
Conclusion: The nanocream containing the newly synthesized POEs was successful for trans-
dermal delivery of piroxicam.
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Introduction
Piroxicam is a nonsteroidal, anti-inflammatory, and analgesic agent. It is a water-
insoluble drug with an acidic pKa value of 5.3. Structurally, the pyridine ring that is 
attached to the amide group also provides a pKa value of 1.86. Therefore, it is possible 
that piroxicam can act as a zwitterionic drug at a certain pH value. As a weak acid, 
piroxicam ionizes at pH 7.4 and at physiologic pH.1 It has a log P value of 1.8.2
It is well known that, when drug molecules are transported through the skin, they 
undergo two processes, starting with drug penetration through the stratum corneum 
followed by drug diffusion into the deeper tissues. The rate and extent of drug   transport 
through the stratum corneum depends on the size, log P, ionic strength, hydrogen 
bonding ability, and physicochemical properties of the vehicle.3
The correlation between the physicochemical properties of nonsteroidal anti-
inflammatory drugs (NSAIDs) and the extent of their absorption from the skin has been International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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confirmed by many investigations.4,5 These studies have found 
that the log P value of NSAIDs seems to be the most impor-
tant factor compared with their pKa value and   molecular 
weight. This can be related to the relatively comparable pKa 
and molecular weight of all NSAIDs and their highly variable 
log P values. Piroxicam with a log value of P 1.8 has shown 
a higher plasma concentration after topical administration in 
rats compared with NSAIDs of log P value $ 3.5. Drugs with 
a log P value of around 2 are   suggested to be good candidates 
for topical delivery.6
The enhancement of transdermal piroxicam transport 
has been extensively investigated. Various techniques have 
been used, including ion pairing,7 pretreatment of the skin 
with permeation enhancer,8,9 inclusion into a carrier system 
with drug ionization,10–12 and application of permeation 
enhancement.13,14
Microemulsions and nanoemulsions have many advan-
tages for use as topical drug delivery systems. Firstly, 
the main advantage of these dosage forms is that a large 
amount of drug can be incorporated into the formula-
tion due to the increased solubilization capacity, thereby 
enhancing thermodynamic activity in the skin. Secondly, 
the permeation rate of the drug can be enhanced by using 
a micro/nanoemulsion due to the synergistic effect of vari-
ous components to enhance drug delivery across the skin. 
Thirdly, the main   ingredients, ie, oil, water, and surfactant 
mixtures, or surfactant-  cosurfactant mixtures, can be com-
bined   synergistically to enhance drug flux.15
Palm oil esters (POEs)a are constituents of a modified 
palm oil synthesized by reaction with olyel alcohol to produce 
long ester chains of the original triglyceride palm oil. It has 
been reported that POEs have a skin hydration activity of 
40.7% within 90 minutes of application.16 Skin hydration is 
known to enhance transdermal drug delivery.
In the present study, we investigated the suitability of 
newly prepared domestic POEs to act as an internal phase for 
topical delivery of piroxicam in a nanocream formulation. We 
further compared the effect of the external phase on the per-
meation of piroxicam from these nanocream-based POEs. We 
also compared the potential of the formulated topical nano-
cream to deliver piroxicam with that of the currently marketed 
formula. Experimentally, we assessed the in vitro transfer 
of the prepared piroxicam nanocream through an   artificial 
cellulose acetate membrane and full thickness rat skin using 
the marketed gel formula as a   reference.   Furthermore, the in 
vivo anti-inflammatory and analgesic activities of the tested 
and the commercially   available   preparation were measured 
and compared.
Materials and methods
Materials
Potassium dihydrogen phosphate and sodium hydroxide 
were supplied by R M Chemicals (Essex, UK), while the 
orthophosphoric and hydrochloric acids were supplied by 
BDH (London, UK). In addition, acetonitrile was purchased 
from JT Baker (Phillipsburg, NJ), and the POEs was a gift 
from the Universiti Putra Malaysia, Selangor, Malaysia. 
Tween 80, Tween 85, Span 20, Span 85, and sodium 
benzoate were purchased from Sigma-Aldrich (Munich, 
Germany), while piroxicam was supplied by Noveltek Life-
science (Tanggu, China). The cellulose acetate membrane 
of 0.2 µm pore size and 13 mm in diameter was purchased 
from Sterlitech (Kent, WA). The ingredients of the refer-
ence formulation, as stated in the product leaflet, were 0.5% 
anhydrous piroxicam, Carbopol®, propylene glycol, ethanol, 
and triethanolamine.
Nanocream preparation
All formulations were prepared using the continental method 
in which the oil and surfactant mixtures were mixed thor-
oughly for 15 minutes at 750 rpm in a beaker. A low-shear 
mixer with three blades (marine-type propeller) was used 
to mix and emulsify the formulae. Piroxicam was added to 
the mixture and mixed for another 30 minutes until it was 
completely dissolved. An aqueous external phase containing 
sodium benzoate was added gradually to the above mixture in 
the beaker. The formula was subsequently mixed for another 
30 minutes. The droplet size of the nanocream preparations 
were measured by photon correlation microscopy using a 
Nanophox particle size analyzer (Sympatec Gmbh, Clausthal-
Zellerfeld, Germany) and Malvern zeta sizer 1000 HAS 
(Malvern Works, Malvern, UK). The polydispersity of the 
formulae were measured using a Malvern zeta sizer 1000 
HAS. Also, transmission electron microscopy (TEM), Leo 
912 AB Eftem (LEO Electron Optics, Oberkochen, Germany) 
was used to confirm the previously measured droplet size and 
to determine the structural appearance of the system.17 Addi-
tionally, the stability of the final formula was assessed under 
different environmental conditions for three months.18
Nanocreams of 0.5% w/w piroxicam were prepared using 
POEs as the oil phase, phosphate-buffered saline (0.2M), 
pH 4.0, pH 6.0, and pH 7.4 as the aqueous phases, and a 
mixture of Tween 80:Span 20 (80:20) HLB 13.72 as the 
aPalm oil esters is the name of the oil used in our experiments and is not a 
mixture of esters.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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surfactant mixture. A ratio of 25:37:38 was selected from 
the triangular-phase diagrams previously constructed as the 
basic composition of oil:aqueous phase:surfactant for the 
production of nanocream with the best properties (data not 
shown).17 Phosphate-buffered salines of pH 4, pH 6, and pH 
7.4 were used as the external aqueous phases for formulae 
F1, F2, and F3, respectively. Sodium benzoate 0.01% was 
used as a preservative in all formulae.17
In vitro drug transport through  
cellulose acetate membrane
The in vitro drug transport through the artificial cellulose 
acetate membrane (molecular weight cutoff 1000 Da) was 
carried out using a horizontally static type Franz diffusion 
cell. Franz diffusion cells are characterized by an effec-
tive diffusion surface area of 0.636 cm2 and a receptor cell 
  volume of 5 mL. The static receptor cell was filled with 
5 mL   phosphate-buffered saline (pH 7.4) and was stirred 
with a small magnetic bar at a speed of 500 rpm for uniform 
mixing.19 The receptor compartment was maintained at 
37 ± 0.5°C using a circulating water bath.
Formulae F2, F3, and reference containing 0.5 mg of 
piroxicam in amounts of 100 mg were placed on the cellulose 
membrane surface facing the donor compartment, and 400 µL 
samples were withdrawn from the receptor com  partment at 
predetermined time points of hours 0.16, 0.33, 0.5, 1, 2, 3, 4, 
5, 6, and 8. The 400 µL sample withdrawn was replaced by 
fresh phosphate-buffered saline (pH 7.4) and maintained at 
37 ± 0.5°C.20 The drug content in the collected samples was 
determined by a validated high-pressure liquid chromatography 
method. All experiments for each sample were carried out in 
triplicate. The chromatographic conditions used for analysis 
were as follows: the mobile phase consisted of 5 mM diso-
dium hydrogen phosphate adjusted to pH 3 with concentrated 
orthophosphoric acid, methanol, acetonitrile, and glacial acetic 
acid at ratios of 27:20:52:1, respectively. The flow rate was 1 mL/
min, and samples were detected by an ultraviolet-visible detec-
tor at a wavelength of 350 nm. The retention time of piroxicam 
was 4.7 minutes. The limit of detection was 0.035 µg/mL and 
the limit of quantification was 0.0625 µg/mL.
In vitro drug transport across  
full thickness rat skin
In vitro drug transport through full thickness rat skin was 
achieved using the horizontally static-type Franz diffusion 
cell under the experimental conditions mentioned earlier. 
Male Wistar rats weighing 200–250 g were used in this study. 
All experimental procedures were in accordance with the 
Guidelines of the Animal Ethical Committee of Universiti 
Sains Malaysia and had its approval. Rats were anesthetized 
using sodium pentobarbitone 60 mg/kg intraperitoneally. 
The abdominal skin was shaved using electric and hand razors 
then removed surgically. The adherent   subcutaneous fat was 
then carefully cleaned. In order to remove the   extraneous debris 
and leachable enzymes, the skin was immersed in normal 
saline solution (0.9% NaCl) for two hours. The cleaned skin 
was washed with distilled water, wrapped in aluminum foil, 
and stored in a deep freezer at −20°C until further use. Fol-
lowing skin excision, rats were euthanized using an overdose 
of pentobarbitone. The frozen excised full thickness skin was 
brought to room temperature, and thereafter mounted between 
the donor and receptor com  partments of the diffusion cell, with 
the stratum corneum side facing the donor compartment and 
the dermal side facing the receptor compartment.21,22 All other 
experimental steps were sequentially followed as mentioned 
above. Triplicate trials were conducted on all samples tested.
Permeability parameter calculation
Steady-state flux
Flux is defined as the rate of diffusion or transport of a sub-
stance across a permeable membrane. After drug permeation 
has reached steady state, the steady-state flux was calculated 
using the following equation:
  Steady state flux (Jss) = dM/S.Dt  (1)
Where dM is the amount of drug that permeates through 
a unit cross section area, S, per unit time, t.
The slope of the steady-state portion of the permeation 
curve created by plotting the cumulative amount of drug 
permeated in micrograms versus time in hours is the flux.23
Permeability coefficient
The permeability coefficient through the membrane (Kp) was 
determined according to the following equation:
  Permeability coefficient (Kp) = (Jss.H)/C0  (2)
Where H is the thickness of membrane and., C0 is the initial 
drug concentration.
enhancement ratio
This factor was calculated to find the relative enhancement in 
the flux of formulations in respect to the reference enhance-
ment ratio. The enhancement ratio was estimated according 
to the following equation:
Enhancement ratio (Er) =
  Jss formulation/Jss reference  (3)International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Anti-inflammatory activity
The anti-inflammatory activity of the tested preparations 
and the commercially available preparation were   measured 
and compared. Male Sprague-Dawley rats weighing 180–200 g 
were used in this experiment. Measurements of the in vivo 
anti-inflammatory and analgesic activities of the formulae 
conformed with the guidelines and practices of the Animal 
Ethics Committee of Universiti Sains Malaysia, and had its 
approval. The anti-inflammatory action was evaluated using 
the carrageenan-induced hind paw edema method with a slight 
modification.24 Rats were randomly selected and divided into 
four groups of six animals each. These groups were divided, 
according to the formulae administered, into control (vehicle 
base), F2, F3, and reference gel groups. The animals were 
housed in polypropylene cages at 25 ± 1°C and 60 ± 5% rela-
tive humidity, with free access to food and water.
One day prior to application of the trial formulation, the 
hair on the dorsal surface of the rat was shaved. F2, F3, refer-
ence gel, and control formulae were applied on the shaved 
dorsal surface by gentle rubbing for 15 seconds. After five 
hours, 0.1 mL of 1% w/v suspension of carrageenan in normal 
saline was injected into the subplantar region of the right hind 
paw of all control and treated rats. Edema volume, in terms 
of thickness, was measured in all four groups at hours 2, 4, 
and 6 after carrageenan injection using a micrometer (Ozaki 
Ltd, Tokyo, Japan).25 The induced thickness was measured 
by placing the foot of the rat between the anvil and spindle 
of the micrometer.
Mathematically,  the  degree  of  swelling  can  be 
expressed as:
  % change in hind paw thickness = (Ct–C0)/C0 × 100  (4)
Where Ct is hind paw thickness at hours 2, 4, and 6 after injec-
tion of carrageenan, and C0 is the initial hind paw thickness 
before injection of carrageenan.
Analgesic activity
This study was conducted similarly to the anti-inflammatory 
study, except that the pain threshold response of the rat right 
hind paw was measured instead of edematous   thickness. 
The pain threshold was measured prior to and at hours 
2 and 4 intervals after injection of carrageenan using a 
portable pain threshold device (YMF-P1) equipped with a 
data   acquisition system (developed by the Department of 
  Pharmacology, School of Pharmaceutical Sciences, Uni-
versiti Sains Malaysia, Penang, Malaysia). The pressure 
(g) applied to the edematous hind paw caused the rat to 
withdraw its hind paw. The vocalization or struggle of the 
rat was recorded as the pain threshold, as described by Yam 
et al.26 Change in pain threshold (∆g) was calculated as the 
difference in pain threshold before and after injection of 
carrageenan.
statistical analysis
Statistical analyses of steady-state flux across skin, amount 
of drug transferred through the cellulose membrane in vitro, 
and the analgesic and anti-inflammatory effects of the   various 
formulations were performed using one-way analysis of 
variance (ANOVA). A statistically significant difference was 
accepted at P , 0.05.
Results and discussion
Formulation and characterization
Droplet size measurements were found to be less than 140 nm 
for the F1, F2, and F3 formulae as determined by photon 
correlation microscopy. Droplet size was also measured for 
formula F3 by TEM.17 Formula F3 was found to be stable 
for a three-month period at 40°C, 25°C, and 5°C (data not 
shown).18 Formulation F1 was excluded from this study 
because it showed drug precipitation within seven days of 
preparation.18 Only the F2 and F3 formulae were assessed 
for their in vitro activity. The polydispersity index of for-
mulations F2 and F3 were 0.037 ± 0.006 and 0.052 ± 0.009, 
respectively.
Drug transfer across cellulose  
acetate membrane
A drug must be released from its vehicle prior to penetration 
and partition into the skin. For certain formulations, drug 
release from the topical preparation is the rate-limiting step 
for drug absorption. Therefore, to ascertain that drug release 
from the vehicle was not the rate-limiting step for absorption, 
diffusion studies through an artificial synthetic membrane 
using the Franz diffusion cell has been proposed by earlier 
researchers. The membrane used must be inert and porous 
so as to allow drug passage in accordance with molecular 
weight. When drug molecules have a molecular weight as 
small as the pores of the synthetic membrane, they are able 
to pass through it.27,28
Drug transfer rates through the cellulose membranes of 
both nanocream formulae were compared with the transfer 
rate of the commercially available 0.5% piroxicam gel. 
  Figure 1 shows a considerably higher and faster drug transfer 
rate across the membrane for nanocream F3 than for nano-
cream F2. It can be observed that drug transfer through the 
membrane is affected by the pH of the external phase of the 
nanocream. This difference in drug transfer may be attributed International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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to the difference in the solubility of piroxicam at different 
pH conditions. Piroxicam with its weak acidic properties is 
more soluble in pH 7.4 buffer than in pH 6 buffer. Due to its 
high solubility at pH 7.4, partitioning of piroxicam from the 
oil phase to pH 7.4 buffer would be higher, hence leading to 
a higher drug transfer rate.
Diffusion of the drug incorporated into an oil-in-water 
cream or nanocream system is affected by partitioning of the 
drug between the internal oil phase and the external water 
phase. This means that the drug must diffuse from the internal 
phase to the external phase where the drug molecules are free to 
be released. Hence, by increasing drug solubility in the external 
phase, ie, enhancement of drug partitioning from the internal 
oil phase to the external aqueous phase, it is possible to observe 
the driving force for enhanced drug release.29
Because the solubility of piroxicam in the mixed surfac-
tants system of Tween 80 and Span 20 is higher compared 
with that in the POEs and buffers pH 6 and 7.4, the piroxicam 
molecules would then be mainly integrated at the oil water 
interface.30 Therefore, it is expected that drug diffusion to the 
external phase would be faster. The solubility of piroxicam 
in pH 7.4 buffer is about 10 times higher than that in pH 6 
buffer.17 Presumably, partitioning of piroxicam from the oil 
to the pH 7.4 buffer would also be about 10 times higher than 
that in pH 6 buffer. This higher solubility and partitioning 
would be the driving force for the drug to be transferred 
through the membrane at a faster rate. Figure 1 shows that 
100% of the drug was transferred from formulation F3 within 
eight hours, while only 80% of the drug was transferred from 
formulation F2 over the same time period.
Transfer of the drug through the membrane from formula 
F3 was faster, even during the initial hours, than that from 
formula F2. This may be due to the presence of a higher amount 
of soluble piroxicam in the external phase (pH 7.4 buffer) of the 
nanocream.31 In the context of the reference gel, such gels can be 
prepared by various techniques. The simplest method involves 
dispersion of the desired quantity of polymer in the selected 
media and keeping the mixture undisturbed over a certain period 
of time. This is followed by adding the drug initially dissolved 
in a suitable medium. In the case of the reference system, it is 
expected that piroxicam is dissolved in the cosolvent system 
(propylene glycol and ethanol) that is subsequently mixed with 
the previously prepared carbopol dispersion.
The reference showed a comparable release profile to that 
of F3 at eight hours, but was slower during the initial hours of 
release, as indicated by the difference in T50% of drug release 
presented in Table 1. There was a statistically significant dif-
ference (P , 0.05) in T50% between formulation F3 and the 
reference gel. This difference may be due to the swelling of 
polymer in the reference formula, which swells in the presence 
of diffusion fluid, thereby slowing down the release process. 
Generally, polyacrylic acid polymers have a wide range of 
applications in modified-release and external gel preparations. 
This can be attributed to their versatile properties. These 
resins exert their action via different mechanisms. They can 
be pH-sensitive, which makes them soluble under specific 
body conditions, or absorb water, swell, and subsequently 
form a gel network.32 Carbopol, in particular, is widely used 
as a gelling and thickening agent. Its gelling capabilities are 
highly dependent on the neutralization process of the carboxy-
late groups available in the polymer backbone. The higher the 
pH value of the neutralizing agent, the greater the thickening 
ability. Phosphate-buffered saline (pH 7.4) was used to assess 
the in vitro release profile. This media causes the carbopol to 
swell and form a gel network that may impede or reduce the 
release of piroxicam from the reference formula.33
At eight hours, the gel formulation had lost its strength 
and 96% of the drug was released. The high drug transfer 
rate from the reference formulation could be the result of 
free passage of piroxicam dissolved in the medium through 
the pores of the cellulose membrane. The release from the 
reference was higher than that from formulation F2. This 
may be because, as explained earlier, in case of a nanocream 
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Figure 1 Comparative mean in vitro cellulose acetate membrane transport profiles 
of piroxicam from formulations F2, F3 and reference gel. 
Note: Mean ± s.D., N = 3.
Table 1 Mean T50% drug transport across the cellulose acetate 
membrane from different formulations
Formulation T50% (hr)
Formulation F2 4.30 ± 0.249
Formulation F3 3.05 ± 0.244
reference 3.98 ± 0.047
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the drug needs to be partitioned from the inner layer to the 
outer layer before it is released. Presumably piroxicam is 
present in the palisade layer on the inner side of the droplet, 
which may result in controlled release of the drug. As the 
partitioning of the drug into phosphate-buffered saline 
(pH 6) from the oil phase was lower, the release is expected 
to be slower.
Drug transport through rat skin
In vivo measurement of drugs administered transdermally 
is a complex process. This is because some drugs exhibit 
very low plasma concentrations, rendering them impossible 
to be detected using analytical techniques. Problems with 
obtaining ethical approval for in vivo skin studies, as well as 
time constraints and expense, have motivated researchers to 
find an alternative technique for measuring drug permeation 
through skin.34 Hence, in vitro drug permeation through skin 
was introduced as an alternative way to measure drug perme-
ation. Unless the compound is highly lipophilic, the stratum 
corneum is the limiting step for transdermal drug absorption. 
Because drugs are mainly absorbed from the dermis layer, the 
amount of drug that can be transported through the stratum 
corneum can be used to represent the amount of drug that 
enters the systemic circulation.35
Accordingly, topical drugs that exert their effects in 
deeper tissues are best assessed using full thickness skin. 
Undeniably, human skin is the best model for obtaining 
in vitro permeability data. However, lack of availability of 
human skin has caused researchers to shift their attention 
to animal skin as an alternative model. The Wistar rat skin 
model has been used extensively, in view of the fact that its 
stratum corneum thickness, as well as water permeability, is 
similar to that of human skin.36
In our study, drug transport prior to steady state was 
similar for all the formulations during the first three hours, as 
can be seen in Figure 2. From Table 2, it can also be observed 
that the flux of piroxicam during the steady state of formula 
F3 was significantly higher (P , 0.05) than that of formula 
F2 and that of the reference formulation. The most widely 
accepted mechanism by which the nanocream enhances the 
flux is that permeation of the drug-loaded nanocream occurs 
directly via the droplets to the stratum corneum without 
nanocream fusion at the stratum corneum.37 This indicates 
that enhancement of the effect of the nanocream is caused 
by the nanosized droplets dispersed in the continuous phase, 
which can move easily into the stratum corneum and trans-
port the drug through the skin barrier. The oil can enter the 
hydrophobic tail of the stratum corneum bilayer, disturb it 
by creating separate domains, and induce highly permeable 
pathways in the stratum corneum.38 Another possible reason 
for the observed enhancement may be a synergistic effect of 
the nanocream components.15
POEs has been found to have an occlusive effect that can 
induce hydration of the skin combined with the hydration 
effect of water, thereby resulting in increased skin porosity 
which improves absorption.16 A possible explanation for 
this is the presence of an aqueous “pore pathway” consist-
ing of discontinuous domains within the lipid bilayers of 
the stratum corneum, which may expand and interconnect 
to form a continuous “pore pathway” under high hydration 
conditions.37 Accordingly, when piroxicam was prepared in 
a microemulsion form comprising different oil phases, oleic 
acid was the oil of choice for improvement of drug solubility 
and skin permeability through excised rat skin.39
The surfactants used, ie, Tween 80 and Span 20, have 
been found to act as permeation enhancers in different skin 
models.40–42 These surfactants can disturb the lipid bilayers 
of the stratum corneum, thereby making it a less effective 
barrier to drug permeation. Correspondingly, surfactants 
with polyoxyethylene chains have been found to enhance 
permeation of piroxicam through various skin models by 
reversible disturbance of the stratum corneum layer.43 The 
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Figure 2 Comparative mean in vitro rat skin permeation profiles of piroxicam from 
formulations F2, F3 and reference gel.
Note: Mean ± s.D., N = 3.
Table 2 Permeability parameters of the different formulations
Formulation Flux  
(µg/cm2 hour) × 10−3*
Permeability coefficient 
(cm/hour)*
reference   3.10 ± 0.65 0.59 ± 0.12
Formulation F2   4.92 ± 0.26 0.94 ± 0.05
Formulation F3 10.22 ± 0.16 1.95 ± 0.03
Note: *Mean ± standard deviation, n = 3.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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small droplet size of the nanocream may also be correlated 
with an increased permeation rate. This is because of an 
increase in surface contact between the skin and the small 
droplets containing the drug. Kreilgaard has described the 
topical enhancing permeability effect of droplet size by 
comparing formulations containing the same constituents 
but different droplet sizes.44
When the flux of formulations F2 and F3 was compared, 
because both formulations contain equal amounts of oil and 
surfactants, an increase in the pH of the external phase of 
the nanocream seemed to have a high enhancement effect 
on drug permeation through the skin. This result is con-
sistent with the results of previously reported piroxicam 
permeation studies.45,46 When piroxicam was incorporated 
into an   oil-in-water ointment base and the pH of the system 
was adjusted with sodium carbonate from 3.2 to 9.2, there 
was an increase in percutaneous absorption of piroxicam 
through rabbit skin.45 Similarly, a gradual increase in pH 
of topical preparations containing different NSAIDs leads 
to an approximately10-fold increase in their flux. There is 
an assumption that higher absorption of ionized NSAIDs 
is related to an ion-pairing effect.46 It is supposed that ionic 
drugs can form an ion pair with external skin components, 
such as skin fatty acids, and the resulting ion pair would be 
more lipophilic.47,48 Piroxicam could also form an ion pair 
with the buffer components of the external phase of the 
nanocream, ie, sodium hydroxide and potassium dihydro-
gen phosphate, resulting in higher lipophilicity and better 
penetration. Accordingly, the complexity of combining 
piroxicam with diethanolamine to produce ion pairs has 
also been   investigated by pairing of phenolic groups of 
piroxicam and an amine salt, thereby improving drug flux 
through rat skin. Skin permeation enhancement is possible 
because of increased piroxicam solubility.49 The net effect 
of drug solubility in the formulation and its permeation and 
flux through porcine epidermis has also been studied.50 It was 
found that the incorporation of piroxicam into β-cyclodextrin 
or hydroxypropyl β-cyclodextrin increased piroxicam flux 
by several-fold when compared with passive diffusion. On 
the other hand, the incorporation of a piroxicam-cyclodextrin 
complex into a microemulsion system has also been per-
formed, showing that the microemulsion system had a reser-
voir effect on drug release. This is possibly due to the higher 
tendency of piroxicam to dissolve in the oil phase   (isopropyl 
myristate), leading to lesser partitioning of the drug to the 
external phase.29 In other words, the permeation rate of a drug 
from a microemulsion may be increased by using different 
internal phases and composition of a microemulsion, given 
that the affinity of the drug to the internal phase can be   easily 
modified to favor partitioning into the external phase and 
then into the stratum corneum.51
Another assumption for the enhancement of drug 
transfer relates to the transfer of ionized drugs through the 
ionic   channels oriented in the lipid bilayers of the stratum 
corneum.51 The higher transfer of piroxicam from formula 
F3 compared with formula F2 through the cellulose acetate 
membrane may also be related to the difference in permeabil-
ity through the skin, given that drug release from the vehicle 
is essential for determination of drug permeability in skin.
Anti-inflammatory activity
NSAIDs administered topically penetrate the skin slowly 
and pass in small quantities into the systemic circulation. 
The bioavailability of NSAIDs after topical application is 
generally less than 5%–15% compared with equivalent oral 
administration. On the other hand, the ability of NSAIDs to 
reach deeply into the affected tissue to induce a topical local 
effect is still debatable. The multilayered composition of skin 
renders the extent of penetration of various drugs different at 
different skin levels. Generally, most drugs are applied with 
the purpose of enhanced topical delivery to target underlying 
tissues. For example, NSAIDs cannot accumulate sufficiently 
at the specified tissue because of absorption through the 
blood vessels in the dermis layer, preventing the drug from 
penetrating further into deeper tissues.52
Correspondingly, it has been found that topical admin-
istration of NSAIDs leads to a relatively high concentration 
in the dermis as compared with the oral route.53 The ability 
of piroxicam to achieve local enhanced delivery via topical 
application has been studied by McNeill et al.52 A comparison 
was made between the muscle content of piroxicam beneath 
the area of topical application with that after an intravenous 
dose. It was found that topical application of piroxicam could 
achieve high local concentrations than the intravenous dose. 
The peak concentration of piroxicam in muscle was attained 
four hours after topical application and 12 hours after intra-
venous administration. Therefore, plasma drug concentra-
tions achieved locally may not reflect drug bioavailability. 
In this situation, in vivo pharmacodynamic measurement 
(of anti-inflammatory and analgesic properties) may be of 
prime importance.54
It can be seen in Figure 3 that formula F3 showed a 
  significantly higher (P , 0.05) anti-inflammatory effect 
compared with the control, reference, and F2 formulae 
at two-, four-, and six-hourly intervals after injection of 
  carrageenan. These results correlate well with in vitro results International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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for aceclofenac reported previously by Shakeel et al.55 Flux 
across the skin for formula F3 was nearly 3.3-fold higher 
than that obtained from the reference. The greater the flux 
across the skin, the greater the anti-inflammatory activity. 
Higher permeability indicates a greater amount of piroxicam 
available to generate an anti-inflammatory effect at the area 
of injection. Formula F2 also showed a significantly greater 
effect than that of the reference formulation (Table 2) .
Both formulae F2 and F3 showed higher anti-inflam-
matory activity compared with the reference formulation. 
This rapid reaction may be attributed to the lower droplet 
size and the cumulative effect of the excipients used which 
would eventually increase the permeability of the drug. The 
anti-inflammatory effect of formula F3 was higher than that 
of F2. This may correspond to the difference in transport of 
piroxicam through the cellulose membrane and full thick-
ness rat skin.
Analgesic activity
Figure 4 shows that F3 had significantly higher analgesic 
activity (P , 0.05) relative to that of the control, reference, 
and F2 formulae. Prostaglandins play an important role 
in promoting signs and symptoms of inflammation and in 
sensitizing terminal afferent C fibers in the periphery and 
enhancing the response of C fibers to algesic stimuli result-
ing in hyperalgesia.56 Inhibition of the cyclo oxygenase 
enzyme and prostaglandin synthesis can rapidly reverse 
the hyperalgesia, pain, and inflammation.57 Hence, a for-
mula with faster and higher flux could produce a higher 
analgesic effect.
Conclusion
Formula F3 had a high drug transfer rate through a cellulose 
acetate membrane compared with F2 and the reference gel 
during the initial hours of permeation. Both F3 and reference 
gel showed 100% drug release after eight hours of permeation. 
However, formulation F2 and F3 exhibited a higher skin per-
meation flux at steady state compared with the reference gel. 
This may be attributable to the reduced droplet size, along 
with the synergistic effect of the nanocream components 
which may enhance drug permeability. Formula F3 also dem-
onstrated a higher flux compared with F2. This is perhaps due 
to a difference in partitioning of the drug from the internal oil 
phase to the external buffer phase of the emulsion system. The 
higher pH value of the external phase of formula F3 relative 
to that of F2 leads to higher availability of piroxicam in the 
external phase, probably leading to a higher release of the 
drug from formula F3. Furthermore, the study discovered 
that the prepared nanocream formulation of F3 and F2 had 
higher analgesic and anti-inflammatory activity compared 
with the currently marketed gel. The enhanced reaction 
may be due to the smaller droplet size along with increased   
permeability.
Acknowledgments
The authors thank the Institute of Postgraduate Studies, 
  Universiti Sains Malaysia, and the Biopharmacy   Co-operative 
Center for providing financial assistance.
Disclosure
The authors report no conflicts of interest in this work.
%
 
c
h
a
n
g
e
 
i
n
 
h
i
n
d
p
a
w
 
t
h
i
c
k
n
e
s
s
Time (hr)
2 4 6
0
10
20
30
40
50
60
70
Control Formulation F2 Formulation F3 Reference
***
***
***
***
***
***
***
***
**
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on rat hind paw edema at 2, 4 and 6 hours after administration of carrageenan.
Notes:  ***  and  **  indicate  significant  at  P  ,  0.001  and  P  ,  0.01,  respectively. 
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